Selection criteria Participants were adults (≥18 years), with a clinically relevant history consistent with house dust mite (HDM) allergic asthma of at least 1 year prior to trial entry and use of an appropriate amount of ICS (incl. combination products) in accordance with the GINA Guideline step 2-4 e1 for a period of at least 6 months within the past year before randomization. Participants were required to also have a history HDM allergic rhinitis. Additionally a positive skin prick test response to HDM (wheal diameter ≥ 3 mm larger than the negative control), and positive specific IgE against HDM (≥0.70 KU/L) was required.
This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods:
Selection criteria Participants were adults (≥18 years), with a clinically relevant history consistent with house dust mite (HDM) allergic asthma of at least 1 year prior to trial entry and use of an appropriate amount of ICS (incl. combination products) in accordance with the GINA Guideline step 2-4 e1 for a period of at least 6 months within the past year before randomization. Participants were required to also have a history HDM allergic rhinitis. Additionally a positive skin prick test response to HDM (wheal diameter ≥ 3 mm larger than the negative control), and positive specific IgE against HDM (≥0.70 KU/L) was required.
Participant's asthma control questionnaire (ACQ) score was to be >1 at the first visit implying that participants asthma was not well-controlled on their regular asthma controller medication. At randomization following switching of controller medication to budesonide, ACQ was to be between 1-1.5, implying that asthma was neither well-controlled nor uncontrolled by the ACQ definition e2 . Lung function (defined by FEV 1 ) at randomization was to be ≥70% predicted value.
Other key selection criteria were documented reversible airway obstruction (a: Improvement in absolute FEV 1 ≥12% and ≥200 ml after administration of SABA; b: Improvement in PEF >20% after administration of SABA; c: Diurnal variability in PEF >20%; d: positive bronchial provocation test (exercise, dry air, mannitol, or methacholine induced); a historical test within the last 2 years prior to randomization was acceptable), no clinical history of perennial allergic asthma or rhinitis caused by an allergen to which the participant was regularly exposed and sensitized (except HDM), no clinical history of seasonal allergic asthma or rhinitis if the seasonal allergen was causing symptoms during the ICS reduction period, no hospitalizations for more than 12 hours due to asthma exacerbation within the last 3 months prior to screening visit.
Trial periods
The trial design is shown in eFigure 1. During period 1, eligible participants were switched from their regular asthma controller medication (including combination products) to equivalent doses of ICS (budesonide) e1 and SABA as needed. Throughout period 2 participants received the SLIT-tablet in addition to ICS and SABA. During the last approximately 4 weeks of period 2 (designated period 2B), participants started filling in the electronic dairy; i.e. reported asthma symptoms, PEF, and SABA use on a twice daily basis. Period 3 began in October 2012. During the first half of this period (period 3A), the participants had their daily ICS dose reduced by 50% and for the second half (period 3B) ICS was completely withdrawn in those participants who had not experienced an asthma exacerbation during period 3A. Participants continued treatment with the SLIT-tablet the entire period and had free access to SABA.
Randomization
Randomization was performed by the sponsor, using the SAS ® system for Windows (version 9.3, SAS Institute, Cary, NC), which generates random assignment of treatment groups to randomization numbers. The randomization list was generated by a trial-independent statistician. The randomization list was divided in blocks of 6, i.e. for each 6 numbers there were 2 sets of placebo, 2 sets of 6 SQ-HDM and 2 sets of 12 SQ-HDM in random order. For each country the lowest available randomization numbers were always shipped. In some cases the blocks were split when distributed within countries.
Randomization codes were kept strictly confidential, accessible only to authorized persons until the time of unblinding. A paper copy and the electronic copy were held in a sealed envelope at a trial-independent department. At the end of the trial all code envelopes were collected and reconciliation was performed between the opened code envelopes and any notified code breaks. Only when the trial was completed, the data file verified, and the protocol violations identified, the randomization codes were broken and made available for data analysis.
Sample size calculation
The power calculation was based on the assumption that about 65% of participants in the placebo group would experience an asthma exacerbation. The assumption was based on a small ICS withdrawal trial, in which loss of asthma control developed in 8 of 12 placebo-treated patients over the 10-week period of ICS withdrawal e3 . The clinically relevant effect size could not be found in any literature when the protocol was written. However, based on the available literature on other asthma treatments and unpublished data from a previous HDM SLIT-tablet trial e4 , the expected effect size was estimated in the protocol and formed the basis for the power calculations. A reduction in the hazard rate for time to first asthma exacerbation of approximately 30%, corresponding to a HR of 0.70, was considered clinical relevant. It was estimated that 240 participants per treatment group would provide at least 80% power to detect a difference between HDM SLIT-tablet and placebo of 0.70 in HR for asthma exacerbations at the 5% significance level. With an expected drop out of about 10%, 266 participants should be randomized per treatment group (i.e. a total of 798 participants).
Statistics
The principal statistical software used was SAS ® , version 9.3 (SAS Institute, Cary, NC).
The primary efficacy analysis of the primary endpoint, time to first moderate or severe asthma exacerbation, was performed with a Cox proportional hazards regression analysis. The model was stratified for country and included treatment group as a factor. Based on this model the first hypothesis to be tested was the hypothesis of no difference between the 3 groups: placebo, 6 SQ-HDM and 12 SQ-HDM. The hypothesis was tested with 2 degrees of freedom. The absolute risk was estimated with the Kaplan-Meier probability in the placebo group and via the hazard ratio to the placebo group. The absolute risk reduction was estimated via the hazard ratio as the difference from the KaplanMeier probability in the placebo group. The 95% confidence limits of the absolute risk reduction were derived from the estimated confidence limits of HR.
The full analysis set (FAS) included all randomized participants in accordance with the ICH intent-to-treat principle. The primary analysis was based on the FAS with multiple imputations (MI) of missing data; i.e. all randomized participants who discontinued from the trial during period 2 were included in the FAS-MI analysis as if they were following the same distribution, with regards to the first asthma exacerbation, as the observed placebo group. In practice, all participants who discontinued during period 2 were included as sampled from the placebo distribution of time to first asthma exacerbation during period 3. This was an imputation method that generated multiple copies of the original data set by replacing the missing values using the observed placebo distribution, analyzed them as complete data sets and finally combined the different parameter estimates across the data sets to produce a unique point estimate and standard error, taking into account the uncertainty of the imputation process. This approach follows the EMA guideline on missing data e5 . All secondary analyses were based on the FAS.
In case of premature discontinuation from the trial after the start of period 3, the participant was counted as being 'at risk' from the start of period 3 and until the time of discontinuation, where after the participant was censored from the primary analysis.
Multiplicity was controlled by a pre-specified hypothesis testing strategy. First, the primary analysis of the primary endpoint was controlled by Fisher's least significant difference procedure e6 .
The first hypothesis to be tested was the hypothesis that all 3 groups were equal. If and only if this hypothesis could be rejected at the 5% level, each of the 3 pairwise comparisons could be tested at the 5% level. Then, for the key secondary endpoints a pre-specified order of hypotheses was specified first for 12 SQ-HDM compared to placebo. If primary and all key secondary hypothesis for 12 SQ-HDM compared to placebo could be rejected at the 5% level and the hypothesis for the primary endpoint for 6 SQ-HDM could also be rejected, then the similar order of hypothesis for key secondary endpoints could be tested for 6 SQ-HDM compared to placebo.
Time to first asthma exacerbation by individual criteria, was analyzed in the same way as described for the primary efficacy endpoint, with the exception of right-censoring in case other criteria than the one evaluated were fulfilled. Log-transformed IgG 4 at end of trial was analyzed with a linear mixed effect model including treatment group, baseline value, visit, and treatment group by visit interaction as fixed effects and country and participant as random effects. The response variable was change from baseline in log 10 (IgG 4 ). Analyses of the odds for improvement in ACQ (or AQLQ(S)) controlled for ICS was performed with a logistic regression analysis with treatment group as categorical fixed effect and baseline ACQ (or AQLQ(S)) and ICS as continuous fixed effects covariates. Improvement was defined as a MID improvement (0.5 points change from baseline) in ACQ/AQLQ(S) without an increased dose of ICS or with no MID change in ACQ/AQLQ(S) on less ICS at visit 13 (end of trial). Country was included as a random effect. Last observation was carried forward if data was missing or if participants discontinued the trial. 
